Published: Thu, February 15, 2018
Medical | By Johnnie Horton

Analyst Activity - Credit Suisse Group Reiterates Outperform on Agios Pharmaceuticals (NASDAQ:AGIO)

(AGIO) by 4.17% based on its latest 2017Q3 regulatory filing with the SEC. Following the purchase, the insider now directly owns 1,374,599 shares of the company's stock, valued at approximately $92,098,133. The Eventide Asset Management Llc holds 214,000 shares with $14.29M value, down from 300,800 last quarter. In order to determine directional movement, the 50-day and 200-day moving averages for Agios Pharmaceuticals, Inc. The stock increased 0.42% or $0.32 during the last trading session, reaching $77.25. About 372,255 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since February 15, 2017 and is uptrending. Bessemer Group Inc Incorporated invested in 107 shares. (NASDAQ:AGIO). State Street accumulated 1.26M shares or 0.01% of the stock.

Investors also need to beware of the Alarm.Com Holdings, Inc.

The stock increased 0.44% or $0.34 during the last trading session, reaching $78.31. About 68,920 shares traded. (NASDAQ:IMI) news were published by: which released: "Intermolecular's (IMI) CEO Chris Kramer on Q4 2017 Results - Earnings Call ..." on February 14, 2018, also with their article: "Intermolecular Inc".

Analysts await Agios Pharmaceuticals, Inc. Finally, BidaskClub raised Agios Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, January 16th. Therefore 20% are positive. Anthem Inc had 73 analyst reports since July 27, 2015 according to SRatingsIntel. Goldman Sachs initiated it with "Hold" rating and $11200 target in Monday, July 17 report. The company was upgraded on Friday, November 13 by IBC. (NASDAQ:AGIO) has "Neutral" rating given on Monday, June 26 by Janney Capital. The firm has "Sell" rating given on Thursday, September 14 by J.P. Morgan.

The market experts are predicting a 54.85% rally, based on the high target price ($57) for Alarm.Com Holdings, Inc. shares that is likely to be hit in the 52 weeks. As per Wednesday, May 18, the company rating was maintained by Suntrust Robinson. The stock of Ansys, Inc. ValuEngine raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday, February 2nd. The stock witnessed 1.04% gains, -9.31% declines and -12.69% declines for the 1-month, 3-month and 6-month period, respectively. Robert W. Baird maintained Ansys, Inc. (NYSE:ANTM) earned "Buy" rating by Jefferies on Friday, January 12. (NASDAQ:ANSS) on Friday, September 29 with "Buy" rating.

Investors sentiment decreased to 1.21 in 2017 Q3. (NYSE:JCP) closed up +0.07 points or 2.02% at $3.54 with 8.04 mln shares exchanging hands. It worsened, as 22 investors sold AGIO shares while 44 reduced holdings. Nationwide Fund Advsr reported 0% of its portfolio in Agios Pharmaceuticals, Inc. The number of shares now owned by investors are 49.52 mln. Weiss Multi reported 10,000 shares. Renaissance Tech Limited Liability Company holds 851,600 shares or 0% of its portfolio. Rafferty Asset Management Llc, a New York-based fund reported 678,291 shares. Moreover, Menta Capital Llc has 0.26% invested in the company for 234,827 shares. Parametric Portfolio Assoc Ltd Liability Corporation accumulated 21,565 shares. Franklin invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:ANSS) for 10,001 shares. Rbf Ltd Liability Corp reported 43,071 shares. Given that its average daily volume over the 30 days has been 0.57 million shares a day, this signifies a pretty significant change over the norm. Ameritas Investment reported 0.08% stake. (NASDAQ:AGIO). Bank Of America De holds 0% in Agios Pharmaceuticals, Inc. Lazard Asset Management Ltd Co holds 52,659 shares. Cue Financial Gru invested 1.16% of its portfolio in Ansys, Inc.

Larry Fitzgerald will return to the Cardinals in 2018 rather than retire
Jerry Rice, in first place in both categories, is likely unreachable in both catches (1,549) and yards (22,895). A battered offensive line and an injured Palmer didn't stop Fitzgerald from producing Pro Bowl numbers in 2017.

Since August 22, 2017, it had 0 insider buys, and 22 insider sales for $25.02 million activity.

On Wednesday, January 10th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. (NASDAQ:AGIO) shares with value of $157,500 were sold by Bowden Christopher.

On 1/23/2018 Steven L Hoerter, Insider, sold 25,000 with an average share price of $74.83 per share and the total transaction amounting to $1,870,750.00. Insiders sold a total of 183,114 shares of company stock worth $13,866,025 over the last quarter. Hood River Capital Lc has 0.51% invested in Agios Pharmaceuticals, Inc. Moreover, Coldstream Capital Management Inc has 0.09% invested in the company for 49,436 shares. They expect $-1.65 earnings per share, down 23.13% or $0.31 from last year's $-1.34 per share. Agios Pharmaceuticals Inc has a fifty-two week low of $45.11 and a fifty-two week high of $82.96. Credit Suisse Group increased their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an "outperform" rating in a research report on Thursday, November 2nd. Therefore 75% are positive. The firm earned "Buy" rating on Monday, October 2 by RBC Capital Markets. Needham initiated Agios Pharmaceuticals, Inc. Cowen & Co maintained the stock with "Buy" rating in Tuesday, August 8 report. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Agios Pharmaceuticals by 41.5% in the fourth quarter.

2/14/2018-Oppenheimer was Downgraded by analysts at Oppenheimer from a "Outperform " rating to a " Market Perform" rating. The firm has "Neutral" rating by BTIG Research given on Friday, August 19. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.65) by ($0.16). Agios Pharmaceuticals now has a consensus rating of Buy and a consensus price target of $80.18. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company was maintained on Wednesday, August 5 by Roth Capital.

Bb Biotech Ag increased Regeneron Pharmaceuticals Inc.

Like this: